Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | FFAR3 | O14843 | 2/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | TET2 | Q6N021 | 3/20 | 0.32 |
| ▸ | TET3 | O43151 | 1/20 | 0.32 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.32 |
| ▸ | LCK | P06239 | 1/20 | 0.32 |
| ▸ | FYN | P06241 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 3/20 | 0.31 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28199699 | 0.83 | TDP1 (0.36) | TDP1ALDH1A1THRBTSHR | |
| Methacrylic Acid SCHEMBL9717202 | 0.83 | TSHR (0.41) | TDP1ALDH1A1FFAR3THRBTET2 | |
| Methacrylic Acid SCHEMBL28652423 | 0.83 | TDP1 (0.36) | TDP1ALDH1A1FFAR3THRBTET2 | |
| Methacrylic Acid SCHEMBL30721692 | 0.82 | TDP1 (0.44) | TDP1ALDH1A1FFAR3THRBTET2 | |
| Methacrylic Acid SCHEMBL2581850 | 0.82 | — | — | |
| Methacrylic Acid SCHEMBL129271 | 0.82 | TDP1 (0.44) | TDP1ALDH1A1FFAR3THRBTET2 | |
| Methacrylic Acid SCHEMBL1534331 | 0.82 | TDP1 (0.44) | TDP1ALDH1A1FFAR3THRBTET2 | |
| Methacrylic Acid SCHEMBL346724 | 0.82 | TDP1 (0.44) | TDP1ALDH1A1FFAR3THRBTET2 | |
| Acetic Acid SCHEMBL3228026 | 0.82 | FFAR3 (0.50) | TDP1ALDH1A1FFAR3LCKFYN | |
| Methacrylic Acid SCHEMBL331287 | 0.81 | TDP1 (0.35) | TDP1ALDH1A1FFAR3THRBTET2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100196277-A1 | NANOPARTICLE COMPOSITIONS FOR CONTROLLED DELIVERY OF NUCLEIC ACIDS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2010-08-05 | — | — | US | disclosed |
| WO-2008045486-A2 | NANOPARTICLE COMPOSITIONS FOR CONTROLLED DELIVERY OF NUCLEIC ACIDS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2008-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100196277-A1 | NANOPARTICLE COMPOSITIONS FOR CONTROLLED DELIVERY OF NUCLEIC ACIDS | POLRMT, POLN, POLM | TDP1 1349/4885ALDH1A1 2568/4885FFAR3 1406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.